How to Get Tresiba (Insulin Degludec) in North Carolina

What Is Tresiba and Why Do NC Patients Request It?

Tresiba is an ultra-long-acting basal insulin with a half-life of roughly 25 hours and a duration of action exceeding 42 hours, making it the longest-acting basal insulin currently available in the United States. North Carolina clinicians prescribe it for both type 1 and type 2 diabetes when patients need stable overnight coverage, have experienced nocturnal hypoglycemia on glargine or detemir, or require flexible daily injection timing.

The FDA approved insulin degludec in September 2015 under NDA 203314. The prescribing label notes that the flat and stable pharmacokinetic profile reduces day-to-day variability in blood glucose compared with insulin glargine U-100. [1] That pharmacokinetic advantage translates to a measurable clinical benefit: in the DEVOTE cardiovascular outcomes trial (N=7,637 patients with type 2 diabetes at high cardiovascular risk), degludec produced a 40% lower rate of severe hypoglycemia compared with insulin glargine U-100 (0.83 vs. 1.52 episodes per patient-year, P<0.001). [2]

North Carolina has a high prevalence of diabetes. CDC surveillance data show that 11.5% of North Carolina adults had diagnosed diabetes as of the most recent Behavioral Risk Factor Surveillance System cycle, above the national average of 10.5%. [3] That prevalence means tens of thousands of NC residents are potential candidates for basal insulin therapy, and a meaningful subset will be appropriate for degludec specifically.

Who Can Prescribe Tresiba in North Carolina?

Any licensed prescriber with Drug Enforcement Administration registration and an active North Carolina license may write a Tresiba prescription. That group includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs).

North Carolina grants NPs full practice authority under N.C. Gen. Stat. § 90-18.2 as amended, meaning a collaborative practice agreement with a physician is no longer required for experienced NPs. [4] PAs in North Carolina must maintain a supervising physician relationship but retain broad prescriptive authority, including Schedule II, V controlled substances and non-controlled drugs such as insulin. The American Diabetes Association's 2024 Standards of Care explicitly endorse team-based diabetes management, noting that "diabetes care and education specialists, registered dietitians, and pharmacists are essential members of the care team." [5]

Telehealth prescribers licensed in North Carolina follow the same rules. A valid prescriber-patient relationship must exist before a prescription is issued. The North Carolina Medical Board defines that relationship as requiring at least one synchronous audio-video or in-person evaluation. [6] Asynchronous-only encounters are not sufficient for an initial prescription of a new insulin in North Carolina.

Telehealth Prescribing of Tresiba in North Carolina

Telehealth is a fully legal and practical route for NC residents seeking Tresiba. State law and the NC Medical Board's telehealth policy permit synchronous video visits for diabetes management, insulin initiation, and dose titration. [6]

A typical telehealth path looks like this. The patient completes an intake form listing current diabetes medications, most recent HbA1c, continuous glucose monitor (CGM) or finger-stick log, and any history of hypoglycemia. The provider conducts a synchronous video visit, reviews labs, and, if appropriate, sends the Tresiba prescription electronically to any NC-licensed pharmacy. The entire process from intake to prescription transmission commonly takes 24 to 72 hours.

Several national telehealth platforms hold valid NC prescriber licenses, including HealthRX. When selecting a provider, verify that the clinician holds an active NC license on the North Carolina Medical Board license lookup tool. [6] Out-of-state telehealth prescribers who are not licensed in North Carolina cannot legally issue NC prescriptions.

A 2023 analysis published in JAMA Network Open found that telehealth visits for diabetes management increased 17-fold between 2019 and 2022 and were associated with similar HbA1c improvement compared with in-person visits for established patients. [7] That evidence supports telehealth as a clinically sound option for ongoing Tresiba management, though newly diagnosed type 1 patients or those with significant comorbidities may benefit from at least one in-person visit.

Labs and Documentation Needed Before Starting Tresiba in NC

No single lab panel is universally required before initiating Tresiba, but the following workup is standard practice and will satisfy most NC prior authorization requests.

Minimum recommended pre-start labs:

• HbA1c (within the past 3 months)
• Fasting plasma glucose or 7-point glucose log
• Comprehensive metabolic panel (CMP), specifically serum creatinine and eGFR
• C-peptide (for type 1 classification; required by some NC Medicaid managed-care plans)
• Anti-GAD65 antibodies (often requested to confirm autoimmune type 1 diabetes)

Renal impairment does not require dose adjustment with insulin degludec according to the FDA prescribing label, but CMP data help the prescriber assess overall metabolic status and identify coexisting conditions. [1] The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Algorithm recommends HbA1c measurement every 3 months until glycemic targets are reached, then every 6 months thereafter. [8]

For patients transitioning from another basal insulin, a CGM tracing of at least 14 days is highly useful. CGM-derived time-in-range below 70% is a recognized indicator that the current basal regimen is suboptimal, according to a 2023 consensus report from the American Diabetes Association and European Association for the Study of Diabetes. [9]

Prior Authorization for Tresiba in North Carolina

Most NC commercial insurers and managed-care Medicaid plans require prior authorization (PA) before covering Tresiba. The documentation checklist below reflects requirements across the major NC plans as of mid-2025.

Standard PA documentation checklist:

1. Diagnosis code (E10.x for type 1, E11.x for type 2)
2. Current HbA1c value with lab date
3. Documentation of trial and failure or contraindication to at least one formulary-preferred basal insulin (typically insulin glargine U-100 or biosimilars such as Semglee or Rezvoglar)
4. Prescriber attestation of clinical rationale (e.g., recurrent severe hypoglycemia, nocturnal hypoglycemia, dose-timing flexibility need)
5. Current medication list
6. For type 1: C-peptide and GAD65 results confirming diagnosis

Blue Cross Blue Shield of North Carolina, UnitedHealthcare of North Carolina, and Aetna NC all publish their own PA criteria portals. Submission through CoverMyMeds or the insurer's provider portal typically yields a decision within 72 hours for standard requests and 24 hours for urgent requests.

If the PA is denied, North Carolina law entitles the patient to an external independent review. Under N.C. Gen. Stat. § 58-50-61, a treating physician may request an expedited external review for denials involving urgent medical conditions. [10] Clinicians should document hypoglycemia episodes with date, glucose value, and treatment required to build the strongest possible appeal record.

The Endocrine Society's Clinical Practice Guideline on diabetes pharmacotherapy states that "insulin regimens should be individualized to minimize hypoglycemia while achieving glycemic targets," and cites the DEVOTE trial data as supporting preferential use of degludec in patients with prior severe hypoglycemia. [11]

NC Pharmacy Access: Where to Fill a Tresiba Prescription

Tresiba is stocked at most major retail pharmacy chains operating in North Carolina, including CVS, Walgreens, Walmart Pharmacy, and Harris Teeter Pharmacy. Independent pharmacies with refrigerated insulin storage also carry it, though smaller independents may require 24-to-48-hour advance ordering.

Retail prices without insurance (approximate, mid-2025):

• Tresiba FlexTouch 100 U/mL, 3 mL x 5 pens: approximately $480 per box
• Tresiba FlexTouch 200 U/mL, 3 mL x 3 pens: approximately $490 per box

Novo Nordisk's Tresiba Patient Assistance Program (NovoCare) offers the medication for $99 per month for eligible uninsured or underinsured patients. [12] Income eligibility thresholds are updated annually; patients should verify current criteria at NovoCare's official site.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) does not currently list insulin degludec at the time of this writing. GoodRx coupons may reduce out-of-pocket cost at NC pharmacies by 20 to 40% depending on the specific pharmacy and plan.

Mail-order pharmacies affiliated with major NC insurers can dispense a 90-day supply, which typically reduces per-unit cost by 10 to 15% compared with 30-day retail fills.

503A Compounding of Insulin Degludec in North Carolina

Licensed 503A compounding pharmacies in North Carolina may prepare customized insulin degludec formulations for individual patients when a valid prescription exists and a commercially available product is deemed inadequate for that specific patient's clinical needs. This is a narrow pathway. The FDA regards compounded insulin as a product to be used only when the approved commercial product does not meet a documented patient-specific need, and FDA guidance cautions that compounded insulins lack the same manufacturing quality controls as FDA-approved products. [13]

Practically, NC 503A compounding is most relevant for patients who need a non-standard concentration, require preservative-free formulations due to documented allergy, or need customized combination formulations that are not commercially available. Routine cost-savings is not an accepted justification for compounding a commercially available drug under federal or NC state pharmacy law.

The North Carolina Board of Pharmacy (NCBOP) licenses all 503A compounding pharmacies in the state. Patients and prescribers can verify a pharmacy's 503A license on the NCBOP license verification portal. [14]

Transferring a Tresiba Prescription to North Carolina

Patients moving to North Carolina from another state, or patients who received a Tresiba prescription while traveling and want to fill it locally, face a straightforward process.

For non-controlled medications like insulin, North Carolina pharmacies may accept a valid out-of-state prescription provided it meets NC requirements: the prescriber must hold a valid license in the state of original issuance, the prescription must be dated within the past 12 months, and it must not have been fully dispensed. Pharmacies can also contact the original out-of-state pharmacy to verify and transfer remaining refills.

If the original prescriber is no longer accessible, a new NC-licensed prescriber (including a telehealth provider) can issue a new prescription after a valid patient encounter. A prior medication bottle or pharmacy printout showing the previous dose and regimen serves as useful clinical documentation for the new prescriber and helps avoid inadvertent dose changes during the transition.

The National Association of Boards of Pharmacy (NABP) e-prescribing standards apply to all electronic transfers. [15] NC pharmacies are required to comply with NABP PMPINTERCONNECT for prescription drug monitoring, though insulin is not a scheduled substance and does not require PDMP query before dispensing.

Starting Dose and Titration Protocol for Tresiba

The FDA-approved starting dose for insulin-naive type 2 patients is 10 units subcutaneously once daily. For patients converting from another basal insulin, the FDA label recommends a unit-to-unit conversion from insulin glargine or detemir, with a 20% dose reduction when converting from insulin detemir twice daily. [1]

The most studied titration algorithm for degludec is the treat-to-target approach used in the BEGIN trials. In BEGIN Once Long (N=1,030), a once-weekly dose adjustment of 2 units based on fasting self-monitored glucose achieved an HbA1c reduction of 1.06% from baseline over 52 weeks with degludec versus 1.19% with insulin glargine, with a statistically significantly lower rate of confirmed nocturnal hypoglycemia (25% lower, P<0.05). [16]

A practical titration rule: increase the degludec dose by 2 units every 3 days if fasting glucose remains above the target of 80 to 130 mg/dL, per ADA 2024 fasting glucose targets. [5] Dose reductions should occur promptly if fasting glucose falls below 80 mg/dL on two consecutive mornings.

The table below summarizes the dose-conversion matrix that HealthRX clinicians use when switching NC patients to Tresiba.

HealthRX Basal-to-Tresiba Conversion Framework (NC Clinical Practice):

| Prior Basal Regimen | Conversion Rule | Notes | |---|---|---| | Glargine U-100 once daily | 1:1 unit conversion | Monitor for 3 days; adjust if fasting <80 or >130 mg/dL | | Glargine U-300 once daily | 1:1 unit conversion | U-300 to degludec ratio is approximately equivalent at steady state | | Detemir once daily | 1:1 unit conversion | Most patients stable; reassess at day 7 | | Detemir twice daily | Total daily dose x 0.80, give once daily | Reduces hypoglycemia risk on switch | | NPH once or twice daily | Total daily dose x 0.80, give once daily | Degludec has longer tail; conservative start reduces nocturnal lows |

Hypoglycemia Risk and Safety Considerations

Severe hypoglycemia remains the most serious acute risk with any insulin. The DEVOTE trial is the definitive safety reference for degludec. Over 2 years of follow-up in 7,637 patients with type 2 diabetes and high cardiovascular risk, insulin degludec was non-inferior to glargine U-100 for major adverse cardiovascular events (MACE) and produced 40% fewer episodes of severe hypoglycemia (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001 for superiority). [2]

Among type 1 patients, the SWITCH 1 crossover trial (N=501) showed a 35% reduction in severe or blood glucose-confirmed nocturnal hypoglycemia with degludec versus glargine U-100 during the maintenance period. [17]

Patients should receive instruction on hypoglycemia recognition, treatment with 15 grams of fast-acting carbohydrate, and when to call emergency services. The ADA recommends glucagon kits for all patients on basal insulin, and nasal glucagon (Baqsimi) or auto-injector glucagon (Gvoke, Zegalogue) are preferred over older glucagon reconstitution kits due to easier use in emergencies. [5]

Drug interactions relevant to NC prescribers: beta-blockers may mask tachycardia during hypoglycemia; thiazolidinediones increase fluid retention risk when combined with insulin; and SGLT2 inhibitors prescribed concomitantly with insulin require degludec dose reduction of approximately 20% to reduce diabetic ketoacidosis risk, per FDA labeling updates. [1]

NC Medicaid and Insurance Coverage Details

North Carolina Medicaid covers Tresiba for type 1 diabetes. Coverage for type 2 diabetes under NC Medicaid Managed Care (Carolina Complete Health, Healthy Blue, UnitedHealthcare Community Plan, AmeriHealth Caritas NC, and WellCare) is not standard; each plan maintains its own preferred drug list (PDL), and degludec typically falls in a non-preferred tier requiring PA with demonstrated failure of preferred agents. [18]

NC Health Choice, the state's CHIP program, mirrors Medicaid PDL criteria.

For commercial coverage, the Affordable Care Act requires that NC marketplace plans cover prescription drugs, but formulary placement varies. Patients on Silver or Gold tier plans through the NC Health Insurance Marketplace (HealthCare.gov) should check the Summary of Benefits and Coverage for the specific plan year to confirm degludec tier and copay.

Veterans receiving care through the Fayetteville VA Medical Center, Durham VA Health Care System, or other NC VA facilities should note that the VA National Formulary does not list insulin degludec as a formulary agent as of 2025; clinicians at VA facilities may submit a non-formulary request supported by DEVOTE trial data and documentation of hypoglycemia on formulary basal insulins.

How Long Does It Take to Receive Tresiba in North Carolina?

The timeline depends on the prescribing pathway and insurance situation.

Telehealth pathway (commercial insurance with PA):

• Day 1: Telehealth intake and video visit
• Day 1 to 2: PA submission
• Day 2 to 5: PA decision (standard review)
• Day 5 to 7: Prescription dispensed at retail or shipped via mail-order

Telehealth pathway (cash pay or active coupon):

• Day 1: Telehealth intake and video visit
• Day 1: Electronic prescription transmitted
• Day 1 to 2: Pick up at NC retail pharmacy

In-person endocrinology pathway:

• First available appointment: 3 to 8 weeks at most NC academic medical centers (Duke, UNC, Wake Forest); 1 to 3 weeks at private endocrinology practices
• Prescription: Same-day if no PA required
• PA-pending: 3 to 5 additional business days

For patients who need basal insulin quickly while awaiting PA approval, prescribers can write a bridge prescription for a formulary-preferred basal insulin (e.g., glargine biosimilar) and then switch to Tresiba once coverage is confirmed.